JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB1422

Anti-CD55 antibody [MEM-118]

4

(1 Review)

|

(7 Publications)

Mouse Monoclonal DAF antibody. Suitable for Flow Cyt and reacts with Human samples. Cited in 7 publications. Immunogen corresponding to Cell preparation containing CD55 protein.

View Alternative Names

CD55, CR, DAF, Complement decay-accelerating factor

2 Images
Flow Cytometry - Anti-CD55 antibody [MEM-118] (AB1422)
  • Flow Cyt

Lab

Flow Cytometry - Anti-CD55 antibody [MEM-118] (AB1422)

Human peripheral blood lymphocytes stained with ab1422 (red line). Human whole blood was processed using a modified protocol based on Chow et al, 2005 (PMID : 16080188). In brief, human whole blood was fixed in 4% formaldehyde (methanol-free) for 10 min at 22°C. Red blood cells were then lyzed by the addition of Triton X-100 (final concentration - 0.1%) for 15 min at 37°C. For experimentation, cells were treated with 50% methanol (-20°C) for 15 min at 4°C. Cells were then incubated with the antibody (ab1422, 1μg/1x106 cells) for 30 min at 4°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgM (mu chain) (ab97007) at 1/500 dilution for 30 min at 4°C. Isotype control antibody (black line) was mouse IgM [ICIGM] (ab91545, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >30,000 total events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. Gating strategy - peripheral blood lymphocytes.

Flow Cytometry - Anti-CD55 antibody [MEM-118] (AB1422)
  • Flow Cyt

Supplier Data

Flow Cytometry - Anti-CD55 antibody [MEM-118] (AB1422)

Flow cytometry analysis of human peripheral blood cells labelling CD55 with ab1422.

  • 519 FITC

    FITC Anti-CD55 antibody [MEM-118]

  • 578 PE

    PE Anti-CD55 antibody [MEM-118]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-CD55 antibody [MEM-118]

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

MEM-118

Isotype

IgM

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Cell preparation containing CD55 protein. The exact immunogen used to generate this antibody is proprietary information.

P08174

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "10 µg/mL", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/mouse-igm-b11-7-isotype-control-ab91545'>ab91545</a> - Mouse monoclonal IgM, is suitable for use as an isotype control with this antibody.</p>" }, "Primates": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

Product details

This product was changed from ascites to tissue culture supernatant on 24th Januray 2018. Please note that the dilutions may need to be adjusted accordingly. If you have any questions, please do not hesitate to contact our scientific support team.

Properties and storage information

Form
Liquid
Purification technique
Proprietary technique
Purification notes
Purified from TCS. Purified by precipitation and chromatography. Purity >95% by SDS-PAGE.
Storage buffer
pH: 8 Preservative: 0.097% Sodium azide Constituents: PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD55 also known as Decay-Accelerating Factor (DAF) is a glycoprotein that regulates the complement cascade. This protein typically weighs around 70 kDa. It is expressed in many cells including epithelial and endothelial cells and is often present on the surface of blood cells. CD55 plays an important role in protecting cells against lysis by inhibiting the formation and stability of C3 and C5 convertases which ultimately prevent cell destruction by the complement system.
Biological function summary

CD55 helps maintain immune homeostasis by preventing the complement-mediated damage to host tissues. It functions as a member of the regulators of complement activation (RCA) family. While not necessarily part of a larger protein complex its function is related to other regulatory proteins such as CD46 and CD59 which cooperate to regulate complement activity. The DAF protein's immunology function is instrumental in ensuring that self-cells are not inadvertently attacked by the body's immune system.

Pathways

CD55 significantly impacts the complement pathway which is a central component of the innate immune system. It directly interacts with complement components C3 and C5 accelerating their decay and disassembly. Through this pathway CD55 has a working relationship with other complement regulatory proteins like Factor H which also aids in controlling complement activation on the cell surface.

A dysfunctional CD55 can relate to conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). In PNH the absence or insufficiency of CD55 (and CD59) on red blood cells leads to complement-mediated lysis causing hemolytic anemia. In aHUS impaired regulation of the complement system including abnormalities in CD55 function exacerbates symptoms. CD55's role is therefore important in preventing these complement-related disorders and preserving cellular integrity in the human body.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed : 7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed : 28657829).. (Microbial infection) Acts as a receptor for Coxsackievirus A21, coxsackieviruses B1, B3 and B5.. (Microbial infection) Acts as a receptor for Human enterovirus 70 and D68 (Probable).. (Microbial infection) Acts as a receptor for Human echoviruses 6, 7, 11, 12, 20 and 21.
See full target information CD55

Publications (7)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 13:1058763 PubMed36713440

2023

Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.

Applications

Unspecified application

Species

Unspecified reactive species

Lonneke H Gaykema,Rianne Y van Nieuwland,Mette C Dekkers,Mieke F van Essen,Sebastiaan Heidt,Arnaud Zaldumbide,Cathelijne W van den Berg,Ton J Rabelink,Cees van Kooten

Arthritis research & therapy 22:24 PubMed32051018

2020

Tumour necrosis factor alpha promotes secretion of 14-3-3η by inducing necroptosis in macrophages.

Applications

Unspecified application

Species

Unspecified reactive species

Gulzhan Trimova,Kaoru Yamagata,Shigeru Iwata,Shintaro Hirata,Tong Zhang,Fumi Uemura,Minoru Satoh,Norma Biln,Shingo Nakayamada,Walter P Maksymowych,Yoshiya Tanaka

Clinical and experimental immunology 191:116-124 PubMed28940198

2017

Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Applications

Unspecified application

Species

Unspecified reactive species

L Cheng,S-J Gou,H-Y Qiu,L Ma,P Fu

Oncology letters 12:1507-1512 PubMed27446461

2016

Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells.

Applications

ICC/IF

Species

Human

Lucyna Kapka-Skrzypczak,Sylwia Popek,Krzysztof Sawicki,Ewa Wolińska,Magdalena Czajka,Maciej Skrzypczak

PLoS pathogens 10:e1004412 PubMed25254972

2014

Exploitation of the complement system by oncogenic Kaposi's sarcoma-associated herpesvirus for cell survival and persistent infection.

Applications

ICC/IF

Species

Human

Myung-Shin Lee,Tiffany Jones,Dae-Yong Song,Jae-Hyuk Jang,Jae U Jung,Shou-Jiang Gao

Clinical cancer research : an official journal of the American Association for Cancer Research 15:851-7 PubMed19188155

2009

In vivo model of follicular lymphoma resistant to rituximab.

Applications

Unspecified application

Species

Unspecified reactive species

Stéphane Dalle,Sophie Dupire,Stéphanie Brunet-Manquat,Lina Reslan,Adriana Plesa,Charles Dumontet

Journal of immunology (Baltimore, Md. : 1950) 149:2262-70 PubMed1382093

1992

The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases.

Applications

Unspecified application

Species

Unspecified reactive species

T Cinek,V Horejsí
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com